British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.

GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in patients with multiple myeloma at or after first relapse. The study is evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone,

Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first treatment didn’t work or who had severe side effects.

The results will be welcomed by boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and vaccines.

GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain patients with multiple myeloma. Read more here.